secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001213900-21-039285
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma reports Q2 2021 net loss $2.3M; cash $79.6M; positive LP-184 pancreatic data
--------------------------------------------------------------------------------

- Net loss $2.3M ($0.21/sh) vs $833K ($0.31/sh) in Q2 2020; R&D expenses rose to $1.16M.
- Cash, equivalents, and marketable securities $79.6M at June 30, up from $19.2M Dec 31, 2020.
- Preclinical data for LP-184 showed 93% avg tumor volume reduction in pancreatic cancer models.
- Preparing LP-300 Phase 2 trial site selection and GMP batch for NSCLC in Q3 2021.
- Reacquired LP-100 (Irofulven) rights from Allarity; $1M upfront plus up to $16M milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000121390021039285/0001213900-21-039285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000121390021039285/ea144935-8k_lanternpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-039285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer